Jocasta Neuroscience
Jocasta Neuroscience raises $35M Series A at $150M valuation
Quick Facts
Jocasta Neuroscience: Series A Funding Round
Jocasta Neuroscience has successfully raised $35M in Series A funding, reaching a valuation of $150M.
Company Overview
Developing longevity protein for neurodegenerative conditions
Funding Details
The Series A round was led by Andreessen Horowitz bio, with participation from Khosla Ventures.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2023
- Employees: 50+
- Category: Biotech
Investment
Jocasta Neuroscience plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Andreessen Horowitz bio: Verified investor in Series A
- Khosla Ventures: Verified investor in Series A
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...